These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32280098)

  • 1. Low Dose Brain Irradiation Reduces Amyloid-β and Tau in 3xTg-AD Mice.
    Wilson GD; Wilson TG; Hanna A; Fontanesi G; Kulchycki J; Buelow K; Pruetz BL; Michael DB; Chinnaiyan P; Maddens ME; Martinez AA; Fontanesi J
    J Alzheimers Dis; 2020; 75(1):15-21. PubMed ID: 32280098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cranial irradiation significantly reduces beta amyloid plaques in the brain and improves cognition in a murine model of Alzheimer's Disease (AD).
    Marples B; McGee M; Callan S; Bowen SE; Thibodeau BJ; Michael DB; Wilson GD; Maddens ME; Fontanesi J; Martinez AA
    Radiother Oncol; 2016 Jan; 118(1):43-51. PubMed ID: 26615717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tau passive immunization inhibits not only tau but also Aβ pathology.
    Dai CL; Tung YC; Liu F; Gong CX; Iqbal K
    Alzheimers Res Ther; 2017 Jan; 9(1):1. PubMed ID: 28073379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease.
    Manczak M; Reddy PH
    Hum Mol Genet; 2012 Dec; 21(23):5131-46. PubMed ID: 22926141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer's Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?
    Merino JJ; Muñetón-Gómez V; Alvárez MI; Toledano-Díaz A
    Curr Alzheimer Res; 2016; 13(4):403-12. PubMed ID: 26567742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model.
    Herline K; Prelli F; Mehta P; MacMurray C; Goñi F; Wisniewski T
    Alzheimers Res Ther; 2018 Jun; 10(1):54. PubMed ID: 29914551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3×Tg-AD Mice Overexpressing Phospholipid Transfer Protein Improves Cognition Through Decreasing Amyloid-β Production and Tau Hyperphosphorylation.
    Wang WZ; Li MW; Chen Y; Liu LY; Xu Y; Xia ZH; Yu Y; Wang XD; Chen W; Zhang F; Xu XY; Gao YF; Zhang JG; Qin SC; Wang H
    J Alzheimers Dis; 2021; 82(4):1635-1649. PubMed ID: 34219730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active full-length DNA Aβ
    Rosenberg RN; Fu M; Lambracht-Washington D
    Alzheimers Res Ther; 2018 Nov; 10(1):115. PubMed ID: 30454039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SLOH, a carbazole-based fluorophore, mitigates neuropathology and behavioral impairment in the triple-transgenic mouse model of Alzheimer's disease.
    Wu X; Kosaraju J; Zhou W; Tam KY
    Neuropharmacology; 2018 Mar; 131():351-363. PubMed ID: 29309769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ca2+-permeable TRPV1 pain receptor knockout rescues memory deficits and reduces amyloid-β and tau in a mouse model of Alzheimer's disease.
    Kim J; Lee S; Kim J; Ham S; Park JHY; Han S; Jung YK; Shim I; Han JS; Lee KW; Kim J
    Hum Mol Genet; 2020 Jan; 29(2):228-237. PubMed ID: 31814000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model.
    Hirata-Fukae C; Li HF; Hoe HS; Gray AJ; Minami SS; Hamada K; Niikura T; Hua F; Tsukagoshi-Nagai H; Horikoshi-Sakuraba Y; Mughal M; Rebeck GW; LaFerla FM; Mattson MP; Iwata N; Saido TC; Klein WL; Duff KE; Aisen PS; Matsuoka Y
    Brain Res; 2008 Jun; 1216():92-103. PubMed ID: 18486110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human tau increases amyloid β plaque size but not amyloid β-mediated synapse loss in a novel mouse model of Alzheimer's disease.
    Jackson RJ; Rudinskiy N; Herrmann AG; Croft S; Kim JM; Petrova V; Ramos-Rodriguez JJ; Pitstick R; Wegmann S; Garcia-Alloza M; Carlson GA; Hyman BT; Spires-Jones TL
    Eur J Neurosci; 2016 Dec; 44(12):3056-3066. PubMed ID: 27748574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knockout of 5-lipoxygenase prevents dexamethasone-induced tau pathology in 3xTg mice.
    Joshi YB; Chu J; Praticò D
    Aging Cell; 2013 Aug; 12(4):706-11. PubMed ID: 23634895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble Conformers of Aβ and Tau Alter Selective Proteins Governing Axonal Transport.
    Sherman MA; LaCroix M; Amar F; Larson ME; Forster C; Aguzzi A; Bennett DA; Ramsden M; Lesné SE
    J Neurosci; 2016 Sep; 36(37):9647-58. PubMed ID: 27629715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice.
    Oddo S; Caccamo A; Cheng D; Jouleh B; Torp R; LaFerla FM
    J Neurochem; 2007 Aug; 102(4):1053-63. PubMed ID: 17472708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aβ-induced acceleration of Alzheimer-related τ-pathology spreading and its association with prion protein.
    Gomes LA; Hipp SA; Rijal Upadhaya A; Balakrishnan K; Ospitalieri S; Koper MJ; Largo-Barrientos P; Uytterhoeven V; Reichwald J; Rabe S; Vandenberghe R; von Arnim CAF; Tousseyn T; Feederle R; Giudici C; Willem M; Staufenbiel M; Thal DR
    Acta Neuropathol; 2019 Dec; 138(6):913-941. PubMed ID: 31414210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of amyloid beta by Aβ3-10-KLH vaccine also decreases tau pathology in 3×Tg-AD mice.
    Zhang HY; Zhu K; Meng Y; Ding L; Wang JC; Yin WC; Yan Y; Cao YP
    Brain Res Bull; 2018 Sep; 142():233-240. PubMed ID: 30077729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroprotective Effect of SLM, a Novel Carbazole-Based Fluorophore, on SH-SY5Y Cell Model and 3xTg-AD Mouse Model of Alzheimer's Disease.
    Wu X; Kosaraju J; Zhou W; Tam KY
    ACS Chem Neurosci; 2017 Mar; 8(3):676-685. PubMed ID: 28032988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer's disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline.
    Clausen A; Xu X; Bi X; Baudry M
    J Alzheimers Dis; 2012; 30(1):183-208. PubMed ID: 22406441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological modulation of GSAP reduces amyloid-β levels and tau phosphorylation in a mouse model of Alzheimer's disease with plaques and tangles.
    Chu J; Lauretti E; Craige CP; Praticò D
    J Alzheimers Dis; 2014; 41(3):729-37. PubMed ID: 24662099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.